Furthermore, innovations in product formulations, such as non-drowsy and extended-release options, and targeted solutions for niche health needs have supported market expansion. Europe pharmaceutical market is witnessing steady growth, led by Germany, France, and the UK. The region benefits from strong regulatory frameworks, government funding for biopharma research, and increased adoption of biosimilars and orphan drugs. Market growth is driven by the rising prevalence of chronic diseases, aging populations, and expanding access to healthcare.
The biosimilars market will continue to expand as losses of exclusivity occur, with expected launches and uptake forecast to increase overall spending on biosimilars to $20-49 billion in 2027 (Figure 5). A curation of IQVIA’s best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market. Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions. In 2022, specialty product growth outpaced traditional product growth, with a 51% share of total non-discounted spend (Figure 1). In the moving annual total (MAT) to January 2023 (MAT January 2023), specialty spend grew by 11.7% while traditional growth grew 7.3% on an invoice price basis.
Distribution Channel Market Insights
The term “off label” generally refers to the promotion of a Product Type for uses that are inconsistent with the FDA-approved labeling or PI. This can relate to the promotion of uses, dosing/administration, or patient population that are not FDA approved. Apart from that, in Chile, prescription drug advertising and promotion are monitored and regulated by the Agencia Nacional de Medicamentos (ANAMED), also known as the National Drug Agency. ANAMED is a part of the Institute of Public Health (ISP) and is responsible for the control of pharmaceuticals, cosmetics, and medical devices, guaranteeing their quality, safety, and effectiveness. Despite theseadvantages, the sector faces regulatory challenges and quality concerns thathinder growth. Concerns about the safety and long-term side effects ofprolonged generic medication use have led to doubts among healthcare providers abouttheir effectiveness.
- The policy-driven market of China’s VBP requires a focus on cost and scale that is fundamentally different from the needs of the U.S. market, where navigating patent law and the IRA’s pricing provisions is paramount.
- Success in this environment requires not only operational excellence and scale but also sophisticated strategic planning, astute portfolio management, and a deep understanding of the intellectual property landscape.
- For example, Total Eren’s planned 112-megawatt wind farm in San Marcos de Colón, Honduras, underscores the region’s commitment to renewable energy.
- In response to the pandemic, major pharmacy chains like Walmart, Walgreens Boots Alliance, CVS Health and Rite Aid have reported a sharp increase in demand for flu shots in their U.S. pharmacies in 2020, in some cases double from the previous year.
Prescription Drug Statistics – Trends In Usage
- The Centers for Disease Control and Prevention (CDC) estimate that every year, over 790,000 Americans suffer from a heart attack; of them, about 580,000 experience their first heart attack and 210,000 experience their second.
- By age group, the children & adolescent segment is estimated to witness strong growth during the forecast period.
- The sheer scale of this opportunity ensures a robust pipeline for generic manufacturers and acts as a powerful catalyst for market growth, triggering intense R&D activity and strategic planning years in advance of the actual patent expiry dates.
- The authors’ thorough analysis has identified potentially groundbreaking new treatments and emerging developments poised to significantly impact the pharmaceutical industry in 2025.
- The injectionsegment in the generic drugs market is experiencing substantial growth due toincreasing demand for biologics, the rising prevalence of chronic diseases, andadvancements in injectable drug formulations.
This risingoccurrence of cancers, diabetes, cardiovascular disease, and other suchconditions in an increasingly geriatric population is leading to a growingburden of healthcare expenses. Generic drugs provide a subsidized alternativefor treatments of these essential medications, making them more accessible,especially for low-income countries and other emerging economies. Governmentsand insurance providers actively promote the use of generics to reduce overallhealthcare expenditure. The Asia-Pacific market is expected to grow at the highest CAGR during the forecast period, driven by a rapidly aging population and rising cases of eye disorders like glaucoma and diabetic retinopathy. Improved healthcare infrastructure and increasing awareness about eye health are boosting demand for effective treatments. Additionally, advancements in pharmaceutical technology and expanding access to healthcare in emerging countries are fueling market growth, making Asia-Pacific a key region for ophthalmic drug development and sales.
Hospital And Health Systems
This is in line with an overall trend for growth in retail to be driven by chain and food in recent years. The increasing approvals in the industry are expected to offer an attractive opportunity for market growth during the forecast period. Food and Drug Administration (FDA) authorized ZURZUVAETM (zuranolone) 50 mg for people with postpartum depression (PPD), according to a statement from Biogen Inc. and Sage Therapeutics, Inc. For women with PPD, ZURZUVAE is the first and only oral, once-daily, 14-day medication that can significantly reduce depression symptoms. The U.S. over the counter (OTC) drugs market size was estimated at USD 23.84 billion in 2024 and is predicted to increase from USD 24.81 billion in 2025 to approximately USD 44.17 billion by 2034, expanding at a CAGR of 6.60% from 2025 to 2034. A Morgan Stanley AlphaWise survey, conducted in February and March 2025 among 280 people taking obesity drugs in the U.S., shows patients on weight-loss drugs experience significant changes in their food consumption and preferences.
Rising Incidences Of Chronic Diseases And Infectious Diseases
In addition, we examine a subset of “specialty”drugs (as opposed to “traditional” or“non-specialty” drugs) and then focus on the top 10 percent ofdrugs based on price, i.e., “highest priced drugs”, most, butnot all, of which are specialty drugs. The highest priced drugs were definedon an annual basis, meaning the drugs change for each year of the sample.Table 1 definesthe types of drugs examined in this report. According to the WHO, in 2019, osteoarthritis affected approximately 528 million people globally. Osteoarthritis, characterized by joint pain and stiffness, prompts individuals to seek effective pain relief solutions. OTC analgesics, including pain relievers like acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), become go-to options for individuals managing osteoarthritis symptoms. The widespread availability of these medications without the need for a prescription makes them accessible to a large population, contributing to their role as a driver in the OTC drugs market.
In total, there were 347specialty small molecule drugs in 2017 (19 percent of all small moleculedrugs), which increased to 434 by 2022 (24 percent of all small moleculedrugs). In 2022, 273 specialty small molecule drugs (63 percent) hadonly one manufacturer, 51 specialty small molecule drugs had 2-3manufacturers (12 percent), and 26 specialty small molecule drugs (6percent) had 4-5 manufacturers. The only competition category thatchanged noticeably, as a percentage share of the total, over the sampleperiod was the number of specialty small molecule drugs with 6+manufacturers, which increased from 49 drugs in 2017 to 84 drugs in2022, an increase of 71.4 percent. The cancer segment dominated the overall market, contributing to a revenue share of 17.07% in 2024. Pharmaceutical Market can be attributed to several key factors and trends such as, the rising global incidence of various types of cancer has led to an increased demand for innovative & effective treatments, driving significant investment and research in this area. In addition, advancements in personalized medicine & targeted therapies have revolutionized cancer treatment, offering higher efficacy and fewer side effects.
Trade In Specific Drugs
Super generics of drug type segment is expected to hold a share of more than 44.18% by 2033 in the global generic drugs market. Increasing prevalence of chronic disorders, rising elderly population based in the world, and growing number of infectious diseases drives the growth of global prescription drugs market. In 2024, North America dominated the market due to a high prevalence of eye diseases like glaucoma and diabetic retinopathy, driven by an aging population. The region’s advanced healthcare infrastructure and strong focus on research and development have facilitated the introduction of innovative treatments. These combined factors have firmly positioned North America as the leading market for ophthalmic drugs. Key factors that are driving the market growth include the rising prevalence of chronic diseases, high utilization of prescription drugs, and the increasing elderly population in the country.
The global generic drug market can be reasonably estimated to grow from a baseline of approximately $450-$500 billion in the mid-2020s to a value exceeding $700-$800 billion by the early 2030s. This corresponds to a blended and sustainable CAGR in the 5% to 8% range, confirming a robust and enduring expansion that outpaces many other mature industries. It then explores the innovation frontier, examining the technological and product-level shifts that are reshaping the industry. A detailed regional analysis follows, offering deep dives into the distinct market landscapes of North America, Europe, and Asia-Pacific.
Prescription Drugs Market Size – Global Industry, Share, Analysis, Trends And Forecast 2022 � 2030
Increased funding enables these manufacturers to enhance their R&D capabilities and bring new generic drugs to the market. In recent years, pharmaceutical sales revenues in the US pharmaceutical market outlook have accounted for nearly half of the global total. Pfizer is one of the companies that provides prescription drug revenues worldwide, heavily boosted by its COVID-19 vaccine Comirnaty.
North America held the dominating prescription drugs during the analysis period of 2022 to 2030. In 2024, the liquid ophthalmic segment led the market due to its ease of application and rapid therapeutic action. Liquid forms, such as eye drops and solutions, allow for direct drug delivery to the eye, ensuring quick relief and high patient compliance. Their widespread use in treating various ocular conditions, including dry eye and glaucoma, along with advancements in preservative-free formulations and multi-dose packaging, have further solidified the market dominance.
World Drug Report 2025
Respiratory disorders can significantly impact daily life, but understanding their types, causes, and the importance of appropriate treatment is critical to managing these conditions effectively. Early diagnosis, lifestyle changes, and medical interventions are crucial in optimizing respiratory health and well-being. It’s crucial to address these underlying causes to manage respiratory conditions effectively.
Key Market Trends & Insights
This is in large part because there are a lot ofgenerics approved by FDA, but only a few biosimilars. And a third difference is that Hatch-Waxmanlinks FDA approval of follow-on applications to brand name drugswith the patents listed in the Orange Book covering those products,but there is no equivalent linkage for biologic reference productmanufacturers. In addition to the differences in the approvalpathways, there are other reasons for differences in competitionbetween generic drugs and biosimilars. For example, generic drugsare significantly easier to manufacture than biological products.Generic drugs are usually synthesized from chemicals meaning eachlot of manufactured drugs is the same.
